Veneto Institute of Oncology (IOV-IRCCS) at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Veneto Institute of Oncology (IOV-IRCCS) brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on improving cell therapy against solid tumours. One line arms CAR T cells with matrix-degrading enzymes to break through the tumour stroma, and another profiles expanded effector lymphocytes cell by cell to find features linked to better activity.

OrganizationESGCT 2026 Attendance
Poster
Wed Oct 28
1:30pm–3:30pm
Endowing CAR-T cells with matrix-degrading enzymes overcomes stromal barriers and eradicates solid tumors
Immunotherapy and CAR T cells
Poster
Wed Oct 28
1:30pm–3:30pm
Single-cell profiling of ex vivo expanded effector lymphocytes reveals cellular and transcriptional features to improve anti-tumor efficacy
Immunotherapy and CAR T cells

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Veneto Institute of Oncology (IOV-IRCCS)

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction